产品
编 号：F744432
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 1365287-97-3
产品详情
生物活性：
Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer.
体内研究：
Emibetuzumab (LY2875358) (10 mg/kg; i.v.; once a week for 5 weeks) inhibits in vivo growth of glioblastoma U87MG xenograft tumors in mice.Emibetuzumab (10 or 20 mg/kg; i.v.; single) downregulates levels of MET and pMET in the tumors of mice.Emibetuzumab (10 mg/kg; i.v.; once a week for 3, 5 or 6 weeks) exhibits antitumor effects on MET-amplified xenograft mouse tumor models.Animal Model:Athymic nude mice (U87MG tumor xenograft model).
Dosage:10 mg/kg
Administration:Intravenous injection, once a week for 5 weeks.
Result:Demonstrated a significant inhibition of tumor growth.
Animal Model:Athymic nude mice (MKN45 xenograft tumor model).
Dosage:10 or 20 mg/kg
Administration:Intravenous injection, single.
Result:Reduced MET and pMET in the tumors by approximately 50% at both the 10 and 20 mg/kg doses by 72 hours post dose, and the reductions persisted to 14 days.
Animal Model:Athymic nude mice (MET-amplified xenograft mouse tumor models).
Dosage:10 mg/kg
Administration:Intravenous injection, once a week for 3, 5 or 6 weeks.
Result:Resulted in a marked reduction in tumor growth in the MKN45/SNU-5/EBC-1 gastric xenograft tumors.
体外研究：
Emibetuzumab (LY2875358) (100 nmol/L; 6 days) inhibits HGF-stimulated proliferation of H596.
Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer.
体内研究：
Emibetuzumab (LY2875358) (10 mg/kg; i.v.; once a week for 5 weeks) inhibits in vivo growth of glioblastoma U87MG xenograft tumors in mice.Emibetuzumab (10 or 20 mg/kg; i.v.; single) downregulates levels of MET and pMET in the tumors of mice.Emibetuzumab (10 mg/kg; i.v.; once a week for 3, 5 or 6 weeks) exhibits antitumor effects on MET-amplified xenograft mouse tumor models.Animal Model:Athymic nude mice (U87MG tumor xenograft model).
Dosage:10 mg/kg
Administration:Intravenous injection, once a week for 5 weeks.
Result:Demonstrated a significant inhibition of tumor growth.
Animal Model:Athymic nude mice (MKN45 xenograft tumor model).
Dosage:10 or 20 mg/kg
Administration:Intravenous injection, single.
Result:Reduced MET and pMET in the tumors by approximately 50% at both the 10 and 20 mg/kg doses by 72 hours post dose, and the reductions persisted to 14 days.
Animal Model:Athymic nude mice (MET-amplified xenograft mouse tumor models).
Dosage:10 mg/kg
Administration:Intravenous injection, once a week for 3, 5 or 6 weeks.
Result:Resulted in a marked reduction in tumor growth in the MKN45/SNU-5/EBC-1 gastric xenograft tumors.
体外研究：
Emibetuzumab (LY2875358) (100 nmol/L; 6 days) inhibits HGF-stimulated proliferation of H596.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备